Functional validation of autoimmune V2G-implicated genes.
(A) Recombinant reporter assay in primary activated CD4+ T cells (N= 7 donors) showing transcriptional activity of the reference vs. risk alleles of the IL2 −128 cRE relative to the URR alone (P<0.0001). (B) Prominent TF motifs predicted to be disrupted (blue) or stabilized (red) by promoter-connected autoimmune SNPs. (C) 3D chromatin-based V2G genes are enriched for CRISPR-implicated genes that regulate CD4+ T cell activation. Observed enrichment of genes regulating multiple aspects of CD4+ T cell activation (IL-2, IL-2 receptor, CTLA-4, IFNg, TNFa or proliferation) from CRISPR screens by Freimer, Schmidt, and Shifrut among sets of 3D chromatin-implicated genes among individual diseases (green, FDR<0.05) or all diseases (purple, FDR<0.05). (D) Enrichment for 3D chromatin-based autoimmune V2G genes among genes with germline knock-out mouse immune (red) and other (black) phenotypes (adjP<0.05, IMPC database). (E) Autoimmune V2G-implicated genes with at least one pharmacologic modulator (rDGIdb). (F) Comparison of the number of manuscripts retrieved from PubMed related to autoimmune disease for each V2G gene with pharmaceutical agents available (x-axis) with an immune-specific expression score computed using the sum GTEX median expression values (v8) for whole blood or spleen divided by other tissues (y-axis). Genes highlighted in red were selected for functional validation in G. (G) Dose-dependent impact of the indicated pharmacologic agents targeting the V2G-implicated genes KISS1R, CHRNB, OXER1, GPR18, GRK6, PTK6, MAP3K11, GPR183, GART, and SIK1 on proliferation of anti-CD3/28 activated murine (left panel) or human (right panel) CD4+ T cells in vitro (N=4).